Medicinal – Page 27

Assessment of Heavy Metals in Mexican Dietary Supplements Using Total X-Ray Fluorescence Spectrometry and Health Risk Evaluation

mycolabadmin

Mexican dietary supplements commonly contain toxic heavy metals like lead, arsenic, and chromium. While individual metal levels in most supplements appeared safe when consumed alone, the cumulative exposure from multiple metals could increase cancer risk over a lifetime. The study found that some popular supplements, particularly those marketed for weight loss and blood detoxification, contained concerning metal levels, especially seaweed-based products and animal-origin supplements. Better regulation and labeling of dietary supplements in Mexico is urgently needed to protect consumers from long-term health risks.

Biphasic Fermentation of Trapa bispinosa Shells by Ganoderma sinense and Characterization of Its Polysaccharides and Alcoholic Extract and Analysis of Their Bioactivity

mycolabadmin

This study investigated fermenting water chestnut shells with a medicinal mushroom called Ganoderma sinense to create a more potent health product. Under optimal fermentation conditions, the resulting material showed significantly improved immune-boosting and antioxidant properties when tested in laboratory cells. The fermentation process changed the structure of polysaccharides and increased beneficial compounds, potentially transforming agricultural waste into a valuable functional food or supplement.

Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT)

mycolabadmin

This study used computer models of brain activity to understand how the psychedelic drug DMT rapidly changes how the brain works during an acute experience. Researchers found that DMT pushes brain dynamics into a special state where the brain becomes hypersensitive to small changes or stimuli. This heightened sensitivity is strongest in brain regions rich in serotonin receptors and matches the expected timing of the drug’s effects, suggesting that brief psychedelic experiences may create lasting changes in the brain through this temporary destabilization window.

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa

mycolabadmin

Two patients with severe anorexia nervosa received psilocybin-assisted therapy and unexpectedly recovered memories of sexual assault that had been unconsciously suppressed. Processing these traumatic memories with professional support led both patients to achieve remission from their eating disorders within three months. This case report suggests that psilocybin may help unlock and heal deeply buried trauma underlying eating disorders, though more research is needed to understand how this works and ensure patient safety.

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review

mycolabadmin

This review examines how ketamine and psychedelics affect connections between brain cells. Under stressful conditions, ketamine and psychedelics appear to strengthen these connections in brain areas important for mood and learning. However, the effects are mixed under normal conditions and vary based on dose, sex, and which specific markers are measured. The findings suggest these substances may help restore brain function damaged by stress or substance use.

Thin-Layer Chromatography (TLC) in the Screening of Botanicals–Its Versatile Potential and Selected Applications

mycolabadmin

This review shows how thin-layer chromatography (TLC), a simple laboratory technique, is invaluable for analyzing plant materials. TLC helps scientists identify which plants are related to each other, find beneficial compounds in herbs, ensure herbal medicines are pure and safe, and track illegal psychoactive plants. Despite being less glamorous than modern equipment, TLC remains practical, affordable, and effective for everyday botanical analysis.

Expanded access to psychedelic treatments: comparing American and Canadian policies

mycolabadmin

This article compares how the United States and Canada allow patients with serious health conditions like PTSD and depression to access experimental psychedelic treatments outside of clinical trials. Canada’s program has allowed over 200 patients to access psilocybin and MDMA treatments since 2022, while the US has only approved 50 patients for MDMA. The authors argue that Canada’s approach is more ethical and accessible, and suggest the US should streamline its process to help more patients who have failed conventional treatments.

Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial

mycolabadmin

Researchers studied how psilocybin affects the way our visual system processes contrast and surrounding visual information. Participants completed vision tests after taking psilocybin or placebo, and the results showed that psilocybin made people more influenced by surrounding visual elements when judging the brightness of objects. Interestingly, the stronger the visual effects people experienced from psilocybin, the more their perception was influenced by these surroundings. This finding might help explain how psilocybin affects mood and could help scientists better understand depression and other conditions affecting vision.

Psychedelics and the Serotonin Hypothesis of Eating Disorders

mycolabadmin

This review explores how psychedelic drugs like psilocybin (found in certain mushrooms) might help treat eating disorders by promoting flexible thinking and breaking rigid eating patterns. The authors summarize evidence from animal studies and early clinical trials showing that psychedelics work differently than traditional antidepressants by triggering brain changes that help people adopt new, healthier behaviors. While results are promising, more research is needed to determine the best doses, patient populations, and long-term safety.

Bioactive Peptides from Quinoa (Chenopodium quinoa Willd.) as Modulators of the Gut Microbiome: A Scoping Review of Preclinical Evidence

mycolabadmin

This review examines how quinoa and its protein-derived peptides can improve gut health by changing the balance of bacteria in the digestive system. Research shows that quinoa helps boost beneficial bacteria, increases diversity of microbial communities, and promotes production of butyrate, a beneficial compound that supports intestinal health. Different disease conditions show specific improvements, such as reduced harmful bacteria in colitis and better metabolic balance in obesity, suggesting quinoa could be tailored for personalized health interventions.

Research Topic: Medicinal